EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Beyond Weight Loss: Rethinking Dietary and Lifestyle Interventions for Liver Disease Modification in MASLD

Abdulrahman Almujaidel, Eman Marzouk iD

Nutrients · 2026

DOI: 10.3390/nu18193202 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, 2026. Verfasst von Abdulrahman Almujaidel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia. Hauptthemen laut MEDLINE: Weight Loss, Life Style, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is commonly managed with dietary and lifestyle intervention, and weight loss is often used as a key marker of treatment success. However, changes in body weight alone do not fully describe the effects of lifestyle intervention on liver disease. This narrative review asks when lifestyle-induced changes can support a claim of liver disease modification. Current guidance generally associates sustained weight loss of at least 5% with reduced liver fat, 7–10% with reduced liver inflammation, and at least 10% with improvement in fibrosis. The review distinguishes weight loss from biological response, pathological improvement, and long-term clinical benefit. It considers how intervention exposure, biological response, outcome type, and duration of follow-up should be interpreted together. It also addresses differences in patient response, long-term adherence, and the limits of different study designs. Randomized trials, long-term observational studies, and target-trial emulation are considered in relation to what they can establish about causality and long-term benefit. We propose a five-question framework for evaluating lifestyle-induced liver disease modification: Who? What? Through which pathway? What outcome? For how long and with what evidence? Weight loss remains an important treatment target, but it should not be considered synonymous with liver disease modification. Claims of disease modification should reflect the level of evidence available. This framework provides a clearer way to distinguish short-term improvement from meaningful and durable modification of MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Weight LossLife StyleFatty LiverNon-alcoholic Fatty Liver DiseaseDietRisk Reduction BehaviorHumansTreatment Outcome

Stichwörter der Autor:innen

causal inferencedietary interventionlifestyle interventionliver disease modificationmetabolic dysfunction-associated steatotic liver diseasephysical activitypublic healthsurrogate endpointstarget-trial emulationweight loss

Autor:innen und Institutionen

  • Department of Public Health, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia.

ORCID-Profile: Eman Marzouk

Zitieren

APA

Almujaidel, A., & Marzouk, E. (2026). Beyond Weight Loss: Rethinking Dietary and Lifestyle Interventions for Liver Disease Modification in MASLD. Nutrients. https://doi.org/10.3390/nu18193202

Vancouver

Almujaidel A, Marzouk E. Beyond Weight Loss: Rethinking Dietary and Lifestyle Interventions for Liver Disease Modification in MASLD. Nutrients. 2026. doi:10.3390/nu18193202

BibTeX
@article{Almujaidel2026,
  author = {Almujaidel, Abdulrahman and Marzouk, Eman},
  title = {Beyond Weight Loss: Rethinking Dietary and Lifestyle Interventions for Liver Disease Modification in MASLD},
  journal = {Nutrients},
  year = {2026},
  doi = {10.3390/nu18193202}
}
Kostenlos starten →